SATB1 and carcinoma: Besides breast cancer, aberrant expression of SATB1 was also correlated with advanced clinicopathologic factors and poor prognosis in cases of glioma, melanoma and carcinomas of stomach, rectum, liver, bladder, and prostate [17]–[21], [25]–[27].